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CM-Path Molecular Diagnostics Forum—consensus
statement on the development and implementation
of molecular diagnostic tests in the United Kingdom
Philip S. Macklin1, Nischalan Pillay2, Jessica L. Lee3, Helen Pitman4, Sophie Scott5, Jayson Wang6, Clare Craig7, J. Louise Jones7,8,
Karin A. Oien9, Richard Colling1,10, Sarah E. Coupland11 and Clare Verrill1,10,12 on behalf of the CM-Path Molecular Diagnostics
working group
BACKGROUND: Pathology has evolved from a purely morphological description of cellular alterations in disease to our current
ability to interrogate tissues with multiple ‘omics’ technologies. By utilising these techniques and others, ‘molecular diagnostics’
acts as the cornerstone of precision/personalised medicine by attempting to match the underlying disease mechanisms to the most
appropriate targeted therapy.
METHODS: Despite the promises of molecular diagnostics, significant barriers have impeded its widespread clinical adoption. Thus,
the National Cancer Research Institute (NCRI) Cellular Molecular Pathology (CM-Path) initiative convened a national Molecular
Diagnostics Forum to facilitate closer collaboration between clinicians, academia, industry, regulators and other key stakeholders in
an attempt to overcome these.
RESULTS: We agreed on a consensus ‘roadmap’ that should be followed during development and implementation of new
molecular diagnostic tests. We identified key barriers to efficient implementation and propose possible solutions to these. In
addition, we discussed the recent reconfiguration of molecular diagnostic services in NHS England and its likely impacts.
CONCLUSIONS: We anticipate that this consensus statement will provide practical advice to those involved in the development of
novel molecular diagnostic tests. Although primarily focusing on test adoption within the United Kingdom, we also refer to
international guidelines to maximise the applicability of our recommendations.
British Journal of Cancer (2019) 121:738–743; https://doi.org/10.1038/s41416-019-0588-1
BACKGROUND
Pathology—the study of disease—has evolved significantly since
its beginnings with Virchow and a purely morphological descrip-
tion of cellular alterations, to our current ability to make fine-
resolution observations at the subcellular/molecular scale.1 We
can now use this knowledge and modern molecular biological
techniques to interrogate human tissue samples in increasingly
sophisticated ways, with the ultimate aim of providing more
accurate diagnoses that can better guide treatment choices. In the
field of cellular pathology, it is now possible to supplement
traditional light microscopic assessment of tissue samples with a
vast array of information at genomic, epigenomic, transcriptomic,
proteomic and metabolomic levels. Thus, molecular diagnostics is
now the cornerstone of precision/personalised medicine, in which
individual patients receive customised healthcare on the basis of
their specific test results, and has the potential to revolutionise
patient care and improve outcomes, as exemplified by its use in
haematological malignancies.2 The application of molecular
diagnostics is currently being expanded into other clinical areas;
for example, in the United Kingdom (UK), the 100,000 Genomes
Project has brought whole-genome sequencing into routine
clinical practice by initially applying this technique to cancer
and rare diseases.3
Despite the promises of molecular diagnostics, significant
barriers have impeded its widespread clinical adoption.4 Until
recently, there has been a lack of national strategy for molecular
diagnostic testing with complex commissioning and funding
arrangements.5 Moreover, the National Health Service (NHS) is
currently poorly equipped to embrace fully this healthcare
revolution. In particular, the substantial attrition of academic
pathology in the UK over the past two decades, coupled with the
increasing service demands placed on pathologists, means that
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many diagnostic laboratories lack the knowledge, expertise and
capacity to introduce these new tests efficiently.6 In addition, the
interaction between clinicians, academia, industry and regulators
required to expedite the development of new molecular
diagnostic tests and their introduction into clinical practice has
not been uniformly present to date.
Inception of a cross-sector molecular diagnostics forum
In 2016, the National Cancer Research Institute (NCRI) launched
its Cellular Molecular Pathology (CM-Path) initiative with the aim
of supporting modernisation of pathology in the UK and, in
so doing, to help to develop the workforce and infrastructure
required to provide nationwide molecular diagnostic services
(https://cmpath.ncri.org.uk). To advance pathology in the UK,
and thus ensure that patients receive the highest quality of care
possible, CM-Path recognises the value of collaborating with
industry, regulators and other key stakeholders. To this end,
members of CM-Path workstream 4 (‘Technology and Infor-
matics’) convened the first meeting of the CM-Path Molecular
Diagnostics Forum on 26th January 2018 at the Royal Society of
Medicine in London. The overarching aims of the forum are as
follows:
● To define infrastructure, regulatory and workflow require-
ments for the adoption of molecular diagnostics in NHS
pathology laboratories;
● To develop protocols to ensure faster and more efficient
implementation of emerging technologies and novel bespoke
and validated molecular panels;
● To assist in the education/training of the workforce required
to provide high-quality, nationwide molecular diagnostic
services;
● To actively engage pathologists with industry and regulators
to develop the next phase of molecular diagnostic tests;
● To form links with companies developing software to assist in
test interpretation and correlation between molecular findings
and clinical outcomes.
Ultimately, we wish to ensure that all patients across the UK
have equitable and rapid access to effective molecular diagnostic
tests, whether developed by industry or academia. The objectives
of this particular meeting, which was attended by 25 individuals
including clinicians, academics and representatives from industry
and regulatory bodies, were to define a ‘roadmap’ for molecular
diagnostic test development and NHS implementation and to
identify the challenges (and their possible solutions) that are likely
to be encountered during these processes. The meeting
commenced with invited case presentations on the development
and implementation of new molecular diagnostic tests in rare
ophthalmic disease (Professor Graeme Black, University of
Manchester) and bladder cancer (Dr Andrew Feber, University
College London), providing illuminating ‘real world’ insights into
these processes. Summaries of the perspectives of industry and of
the National Institute for Health and Care Excellence (NICE) on the
current state of affairs were also presented by Jane Coppard
(public affairs manager at Roche) and Rebecca Albrow (senior
technical adviser in the NICE Diagnostics Assessment Programme),
respectively. It was highlighted that NICE diagnostics guidance
recommendations are typically made by the Diagnostic Advisory
Committee (DAC), an independent decision-making body that
bases its recommendations on review of clinical and economic
evidence. Once recommendations are made, NICE diagnostics
guidance is published on the NICE website7 and is disseminated to
all stakeholders, which include professional societies, patient
organisations and individual clinicians. NICE also creates tools to
support the adoption of guidance but there are many factors that
can hinder nationwide uptake. Until recently, there has been no
systematic method of tracking the use of diagnostics within the
NHS, and therefore, the impact of NICE recommendations cannot
be directly evaluated.
Developing a roadmap for the development and implementation
of new molecular diagnostic tests
In a subsequent breakout session, delegates were grouped by
professional background and tasked to create a roadmap
describing the stages in the development of a new molecular
diagnostic test, from initial concept to clinical implementation.
This is particularly important as, compared with therapeutics, the
validation and approval processes for diagnostic tests are poorly
defined. It quickly became clear that no single group was able to
map the entire pathway, immediately justifying the value of
arranging this multidisciplinary meeting. Ultimately, a final road-
map was agreed by consensus between the groups (Fig. 1); access
to carefully curated tissue specimens through biobanks, health
economics and workforce education are key aspects that have
central relevance to the entire process. The discussions were very
much centred on test development in the UK, although many
companies developing such products are multinational or would
aim to market them internationally. Although not the focus of the
workshop, it was also acknowledged that new diagnostic tests are
often introduced alongside new therapies (as ‘companion
diagnostics’), so the development of novel molecular diagnostic
tests often occurs in parallel to drug development. In this instance,
the clinical need would be very clear and specific at the outset but
otherwise the overall roadmap would still be similar.
Challenges to the implementation of new molecular diagnostic
tests
The groups were then mixed and asked to identify challenges that
are likely to be encountered within the roadmap. Several key
themes emerged during this discussion; importantly, a number of
innovative solutions were also suggested (Table 1).
A follow-up meeting was held in October 2018 to discuss these
challenges in greater detail, and to consider how our roadmap will
likely be impacted by the reconfiguration of genomic laboratory
services within NHS England that took place that month.8 By
creating a single national testing network co-ordinated through
seven Genomic Laboratory Hubs (GLHs), this reconfiguration aims
to expedite widespread adoption of molecular diagnostics into
routine clinical practice and to ensure that such tests are
conducted to uniform standards, thus providing consistent and
equitable care across the country. Building upon the success of
the 100,000 Genomes Project, this project forms part of the
Government’s Life Sciences Strategy,9 and aims to develop a world
leading Genomic Medicine Service within the NHS, as well as to
support scientific research and innovation more broadly. The new
service now includes a National Genomic Test Directory for both
cancer and rare and inherited diseases.10 This directory specifies
which tests are available within the NHS and how they are funded,
which patients are eligible to receive these tests and which
technology platforms should be used to perform each test. The
directory will be updated annually, based on recommendation
from a Clinical and Scientific Expert Panel that will evaluate new
genomic tests and determine which existing tests should be
retired or replaced. The authors believe that this positive
development will help with many of the challenges that we have
identified but, crucially, it only currently covers genetic testing and
not other forms of molecular diagnostics (e.g. infectious disease).
Whilst this new system should help to deliver more uniform
nationwide access to molecular diagnostic tests, some scope for
local flexibility in testing strategy is likely to be of benefit to
patient care. A crucial issue to consider when ordering a molecular
diagnostic test is how this test is best integrated into each
patient’s individual care pathway and we envisage that local
multidisciplinary team (MDT) meetings will continue to play an
important role in making such decisions. Some test results are
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needed more urgently than others and this can influence the type
of test selected and whether this is performed locally or sent
externally. For example, one-step nucleic acid amplification
(OSNA) testing to detect cytokeratin 19 (CK19) mRNA copy
numbers in homogenised axillary lymph node samples, as a
marker of breast cancer sentinel lymph node metastasis, has been
performed in some UK centres for many years, with rapid
intraoperative results determining the requirement for nodal
clearance as part of a one-step procedure.11 Likewise, lung cancer
mutation status can have a significant impact upon immediate
clinical management and rapid in-house testing can be very
useful, particularly in the context of acutely unwell patients or
where a prompt initial screening test result can avoid the need to
perform further unnecessary tests (e.g. KRAS mutations are
generally mutually exclusive with EGFR and ALK mutations in
lung cancer, which therefore do not need to be tested for when a
KRAS mutation is detected).12 Initially, MDTs may also wish to
arrange local funding for specific tests, rather than incur the time
penalty involved in sending samples away. Nevertheless, the
majority of molecular diagnostic tests are generally not urgent (e.g
screening for Lynch syndrome in colorectal cancer)13 and are
therefore likely to be best performed in a centralised reference
laboratory. Furthermore, over time, we hope that the GLHs will
generate evidence to demonstrate that centralised testing can
return results in a clinically relevant timeframe for most
indications. Another reason to retain local testing might be when
a centre has already developed expertise in the performance and
interpretation of a specific test, which could not be delivered to
the same standard through an associated GLH.
It was felt by forum participants that GLHs could play an
important role in the development of novel molecular tests by
providing access to high-quality human tissue samples via linked
academic biobanks and by assisting in test validation, particularly
by facilitating rigorous comparison with established tests and by
recruiting patients into clinical trials. Once an evidence base has
been established, a key milestone for any new molecular test will
be inclusion in the test directory and it is envisaged that this step
could be aligned with approval by the NICE DAC. GLHs will also
12Review technology
1Identify need
(unmet clinical need
or CD) 2Early discovery and
proof of concept
3Testing and
validation
4Formal
consultation on
regulatory
approval/IP
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Fig. 1 Consensus ‘roadmap’ for the development and implementation of molecular diagnostic tests (key: CD= companion diagnostic, IP=
intellectual property). (1) Identify need—researchers define a clinical scenario that would benefit from improved diagnostic capabilities or there is
a specific need for a companion diagnostic test in parallel to drug development; (2) early discovery and proof of concept— preclinical studies to
develop scientific basis of new discovery (we acknowledge that in some cases, this may precede the previous step with clinical relevance only
emerging after the initial scientific discovery); (3) testing and validation—further testing, possibly in preparation for human trials (discussed in
greater detail by Mattocks and colleagues);31 (4) formal consultation on regulatory approval and intellectual property—we recommend
discussions with the relevant regulatory bodies and technology transfer offices at an early stage in test development (e.g., the United Kingdom
Accreditation Service [UKAS] and the Medicines and Healthcare products Regulatory Agency [MHRA]’s Innovation Office),32 to ensure that the
correct procedures are being followed and that intellectual property is protected (N.B. must also consider the need for Research Ethics Committee
[REC] and Human Tissue Authority [HTA] approval, which is required for testing on human tissue samples); (5) identification of position in patient
care pathway—before clinical trials are conducted, it is essential to identify where a new test will fit within the current or redesigned patient care
pathway, not just within the United Kingdom but also other countries, especially Europe and the United States of America; (6) clinical trial
(conducted according to ethical and regulatory frameworks) and clinical outcome data—a formal clinical trial demonstrating equivalence/
superiority to the current ‘gold standard’ diagnostic test may be required; (7) regulatory approval—evidence from proof-of-concept studies and
clinical trials will be required to gain relevant regulatory approval (Conformité Européenne marking of In Vitro Diagnostics [CE IVD] in Europe by
Notified Bodies and the Food and Drug Administration [FDA] in the United Stated of America); (8) commercialisation and commissioning—after
regulatory approval has been granted, the new diagnostic test requires marketing and must be deemed to provide clinical benefit and be cost-
effective (i.e. by the National Institute for Health and Care Excellence [NICE]) before it will be commissioned for clinical use within the National
Health Service [NHS]; (9) implementation—the new test is implemented in clinical practice; (10) quality control—rigorous quality control and post-
marketing surveillance is required to ensure ongoing, high-quality test performance (e.g., in the UK, laboratory accreditation is regulated by UKAS
and external assessment is conducted by International Organization for Standardization [ISO] 17043 accredited external quality assurance
providers [listed at http://www.eptis.org];33 in the specialty of histopathology, this is most commonly undertaken by the United Kingdom National
External Quality Assessment Service [UK NEQAS]); (11) monitor uptake and outcomes—it is important to monitor nationwide uptake of new
molecular diagnostic tests and to provide firm evidence that the tests provide clinical and/or economic benefit; (12) review technology—ongoing
review of the technology, identifying areas for further development/optimisation is essential
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have responsibility for implementing newly approved tests, ideally
working in collaboration with each other to ensure optimal quality
control, and in monitoring test uptake and downstream clinical
effects, for example by transmitting relevant information
derived from genomic MDT meetings to a centralised repository
of outcome data. Likely future challenges for the GLHs
include extending molecular tests to include other ‘omics’
approaches (e.g., epigenomics, transcriptomics, proteomics and
metabolomics) whilst at the same time ensuring standardised,
high-quality performance of established techniques (e.g. PD-L1
immunohistochemistry in non-small-cell lung cancer, for which
several different assays are available).14 This may also entail the
incorporation of digital pathology, which is currently being
promoted via an Innovate UK initiative with the establishment
of five centres of excellence for digital pathology, image analysis
and artificial intelligence.15,16 Such approaches are likely to
Table 1. Challenges to the development and implementation of new molecular diagnostic tests and possible solutions to these
Challenge Solutions
1. NHS commissioning and standardisation of testing
-Limited pathology budgets and current funding structures mean that tests that
could improve patient outcomes (and even save money in the long term) may
not be funded
-Many different tests available (including for the same biomarker), leading to
regional variation in testing
-The timing of investigations within diagnostic/management pathways can
influence the choice of the testing method
-When a new therapy has been recommended by NICE, the NHS should
commission funding for the companion diagnostic test, but this has not always
been the case
-Innovative tests that may have a disruptive effect on the local NHS pathways
may be less likely to be adopted
-Variation in how tissue samples are collected and processed and in how tests
are performed and interpreted
-Lobbying for alternative funding sources and changes to how tariffs are allocated
-Rigorous assessment of different tests, leading to greater understanding of their
strengths and weaknesses, with the aim of uniform adoption of the optimal test
-Within reason, flexibility should be encouraged in the new national testing system to
ensure that patients have access to the most appropriate test at each point in their care
pathway
-Ensure that NICE and the NHS are aligned so that when a new therapy is recommended
by NICE, there is timely uptake of any companion diagnostic test
-Centralised commissioning of testing (as with the recent reconfiguration of genomic
testing within the NHS)
-Development of SOPs and regular participation in EQA schemes
2. Ethical and regulatory issues
-Requirement for ethical approval and consenting procedures during test
development/clinical trials
-Uncertainty about the necessary regulatory requirements (e.g. clinical trial
authorisation, EU IVDR and US FDA approval) for new molecular diagnostic tests
and accreditation of laboratories performing them (uncertainty greater within
academia and NHS than within industry)
-Uncertainty about how ‘Brexit’ will affect regulation of in vitro diagnostics in
the UK (the IVDR, an EU regulation, came into effect in May 2017 and gave
manufacturers 5 years to prepare for a new legislation that will require more
rigorous assessment of in vitro diagnostic medical devices—it is currently
unknown how ‘Brexit’ will affect this)
-Greater clarity with regard to when ethical approval and consent are and are not
required (e.g. test development/validation vs. performance assessment of an already-
validated test)
-Encourage researchers to seek ethical approval at an early stage in test development
-Encourage researchers, clinicians and NHS managers to interact with regulators at an
early stage in test development and implementation (e.g. through MHRA’s innovation
office)32
-Promotion of both UK27 and European28 regulatory guidelines
-Lobbying for clarification of legislative/regulatory impact of ‘Brexit’ and possible
exemptions from new EU regulations, when appropriate
3. Information technology
-Development of standardised, robust IT infrastructures
-Data storage and sharing
-Volume and complexity of data
-Investment in IT infrastructure, ensuring new software is compatible with existing ones
-Consideration of technical, legal and ethical issues to ensure that data can be safely
stored and shared for clinical and research purposes
-Development of novel computational approaches (e.g. AI) to facilitate automated
analyses
4. NHS culture
-Staff must be aware of emerging technologies and willing to adopt them
-Patients should be educated and empowered to ensure that they receive
appropriate molecular testing
-Improved nationwide dissemination of information about established/emerging tests
and funding sources
-Greater communication between specialties (such as at the MDT meeting), to
encourage reflex testing by pathologists, when appropriate
-RCPath to include NICE recommendations in their best-practice guidelines and datasets
-Sharing of case studies demonstrating clinical benefit and cost-effectiveness
-A national workshop involving clinical staff, laboratory scientists and NHS managers
-Education and mentoring of patients and enhanced communication between patients,
clinicians and pathologists (e.g. through the NCRI Consumer Forum)
5. Education/training
-Urgent need to upskill the NHS workforce in molecular diagnostics -Inclusion of molecular diagnostics in UG medical curricula and increased prominence in
PG training, including training of senior staff(CM-Path is actively working to develop
training opportunities in molecular pathology)19,20
-Cross-discipline and cross-sector training to include clinicians, pathologists, nurses,
managers and industry
-Identify best-practice examples in molecular diagnostic training from other countries
6. Monitoring of uptake/response
-Lack of systematic monitoring of molecular diagnostic testing in the NHS,
leading to a knowledge gap regarding current practices across the UK
-Lack of data regarding the clinical impact of test adoption
-NHS genomic reconfiguration to introduce a new molecular diagnostic test directory
and commissioning system
-Inclusion of molecular diagnostics in quarterly NHS England Innovation Scorecard
produced by HSCIC
-Mandatory recording of how new tests have influenced patient care (e.g. treatment
allocation)
AI artificial intelligence, EQA external quality assessment, EU European Union, HSCIC Health and Social Care Information Centre, IT information technology, IVDR
In Vitro Diagnostic Regulation, MDT multidisciplinary team, MHRA Medicines and Healthcare products Regulatory Agency, NICE National Institute for Health
and Care Excellence, NCRI National Cancer Research Institute, NHS National Health Service, PG postgraduate, RCPath The Royal College of Pathologists, SOPs
standard operating procedures, UG undergraduate, UK United Kingdom, USFDA United States Food and Drug Administration
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become part of integrated reporting, bringing together the
clinical, morphological, immunohistochemical and molecular data,
in order to improve diagnostics and patient management.
Centralised testing offers many benefits but there are also
potential downsides to such an approach, and lessons should be
learnt from previous reconfigurations of pathology services.17 Whilst
earlier consolidations have produced cost savings,18 a large initial
financial investment is often required, for example to cover the cost
of new transport networks and to develop the information
technology (IT) infrastructure required to connect different hospi-
tals/laboratories. Critically, the NHS workforce remains central to the
provision of high-quality diagnostic testing and there is a risk of loss
of valuable expertise amongst staff who are not based in GLHs.
Furthermore, sending tissue samples away for testing may
negatively impact upon the ability of ‘non-hub’ centres to contribute
to biobanking activities that are critical to support biomedical
research. Given these risks, and to foster a new molecular medicine
culture within the NHS, it is imperative that the seven GLHs (and
their associated ‘spoke’ hospitals) adopt a collaborative, rather than
competitive, approach to service delivery. Importantly, shared
leadership by pathology, genetic and clinical teams will be needed
to deliver a truly integrated service.
Nationwide delivery of a ‘cutting-edge’ molecular diagnostic
service will require large-scale upskilling of the current laboratory
workforce, as well as amendments to the training of medical
students, junior doctors and clinical scientists. With this requirement
in mind, CM-Path, in collaboration with other relevant organisations,
is actively working to develop training opportunities in molecular
pathology.19,20 Importantly, a requirement for formal molecular
pathology teaching is now included in the Royal College of
Pathologists (RCPath) ‘Curriculum for Specialty Training in Histo-
pathology’;21 a 2-week molecular pathology attachment for histo-
pathology trainees is now advocated22 and trainee knowledge of this
area will be evaluated both through workplace-based assessment
and formal professional examinations. The curriculum is currently
undergoing further revision and it is envisaged that molecular
pathology will feature even more prominently in the next iteration. In
parallel, Health Education England (HEE), in partnership with several
leading UK universities, provides formal postgraduate qualifications
in genomic medicine as part of its Genomics Education Programme,
as well as numerous other online-learning resources (https://www.
genomicseducation.hee.nhs.uk). In addition, a range of professional
training courses in molecular pathology are also available: ‘Molecular
Pathology and Diagnosis of Cancer’ delivered by the Wellcome
Genome Campus and RCPath,23 ‘UK Molecular Diagnostics Training
School’ delivered by the Nottingham Molecular Pathology Node,24
‘Molecular Pathology Study Day’ organised by the British Division of
the International Academy of Pathology (BDIAP)25 and ‘Getting to
Grips with Genomics’ which is a joint initiative between CM-Path,
RCPath and HEE, and importantly, provides education in molecular
pathology to both trainees and trainers alike.26
Finally, legal, accreditation and regulatory frameworks must be
considered when selecting or developing new molecular diagnostic
tests. New in vitro diagnostic devices (IVD) must be approved before
clinical adoption; regulatory guidelines for such approval exist both
within the UK27 and the European Union (EU).28 In the UK, the
Medicines and Healthcare products Regulatory Agency (MHRA) is
responsible for ensuring that medical devices are safe for clinical
use. Currently, there is a Europe-wide transition to the new EU
Regulation on In Vitro Diagnostic Medical Devices 2017/746.29 This
regulation sets out a new pathway for certification that will be
carried out by approved notified bodies and Conformité Europé-
enne In Vitro Diagnostic (CE IVD) approval is a sign of conformity
with European standards. Whilst still to be confirmed, it is likely that
these changes will apply in the UK even after its withdrawal from the
EU. In the UK, all molecular assays and laboratory processes must
also be accredited by the United Kingdom Accreditation Service
(UKAS) through meeting a range of different International
Organization for Standardization (ISO) requirements. UKAS also
requires that IVDs undergo external quality assessment (EQA), with
such quality control exercises most commonly conducted by the
United Kingdom National External Quality Assessment Service (UK
NEQAS). In the United States of America, IVDs are classified based on
likely patient risk and are usually required to undergo premarket
approval (PMA), unless there is a specific exemption.30 Through the
Molecular Diagnostics Forum, for example, CM-Path is working
closely with the MHRA and The British In Vitro Diagnostic
Association (BIVDA) in order to ensure that regulators are involved
at an early stage in the development of new diagnostic tests.
Conclusions and future perspectives
Our NCRI CM-Path Molecular Diagnostics Forum meetings proved
to be highly constructive in identifying strengths and weaknesses
in the application of molecular pathology across the NHS and the
group is committed to facilitate continued collaboration between
pathology (in both the NHS and academia), industry and
regulators. To our knowledge, this is the first cross-sector attempt
at defining the roadmap for molecular diagnostic tests, from
conception through to deployment and use in accredited
laboratories within the NHS. Whilst this process is currently
complex, we believe that many of the challenges that we have
identified can be overcome through closer collaboration between
key stakeholders and with the network of GLHs. The next forum
meeting will have a specific emphasis on addressing optimal
sample handling for molecular testing, how the new ‘hub and
spoke’ arrangement of GLHs will impact upon specimen journey
from patient to laboratory and how molecular testing at GLHs can
be potentially integrated with digital pathology being performed
at the above-mentioned five new centres. Lessons learned will be
integrated into the roadmap, further developing molecular
diagnostic capabilities in the UK.
CM-Path would be delighted to hear from any individual or
group who feel that the Molecular Diagnostics Forum is relevant
to their work and who would like to attend future meetings—
please email cmpath@ncri.org.uk to get in touch.
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